Key result
Aspirin reduced major cardiovascular events by 10% (RR 0.90) compared to placebo or control in people without pre-existing cardiovascular disease, though it increased major bleeding by 55%.
Why the study?
Does aspirin reduce major cardiovascular events in people with no pre-existing cardiovascular disease?
Population
107,686 participants across 14 randomized controlled trials with no pre-existing cardiovascular disease
Comparison
Aspirin vs Placebo or control
Design
Meta-analysis
Follow-up
mean 6.8 years
Authors
Loading...
Supports individualized aspirin decisions in primary prevention; confirms net benefit hinges on ischemic versus bleeding risk balance.
Meta-Analysis (n=107,686)
Does aspirin reduce major cardiovascular events in people with no pre-existing cardiovascular disease?
Effect estimate: RR 0.90 (95% CI 0.85-0.95)
Absolute Event Rate: 4.39% vs 4.74%
p-value: p=<0.01
Aspirin for primary prevention of cardiovascular disease reduces major cardiovascular events and mortality but significantly increases the risk of major bleeding and hemorrhagic stroke, requiring individualized patient decision-making.
Xie et al. (2014) conducted a meta-analysis in Primary prevention of cardiovascular disease (n=107,686). Aspirin vs. Placebo or control was evaluated on Major cardiovascular events (MCE) (RR 0.90, 95% CI 0.85-0.95, p=<0.01). Aspirin reduced major cardiovascular events by 10% (RR 0.90) compared to placebo or control in people without pre-existing cardiovascular disease, though it increased major bleeding by 55%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: